Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile at single cell level of pulmonary endarterectomy surgical specimens from chronic thromboembolic pulmonary hypertension (CTEPH)

ABSTRACT: Endothelial cells are implicated in delayed thrombus resolution. We use single cell RNA sequencing of CTEPH surgical specimens to assess endothelial cell phenotypes that contribute to delayed thrombus resolution.

ORGANISM(S): Homo sapiens

PROVIDER: GSE271435 | GEO | 2025/07/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptome profile of fibroblasts in chronic thromboembolic pulmonary hypertension

Project description:The hallmark of chronic thromboembolic pulmonary hypertension (CTEPH) is fibrotic transformation of pulmonary arterial thrombus, leading to mechanical obstruction of pulmonary arteries. We report the transcriptome profile of fibroblasts isolated from pairs of CTEPH thrombus and pulmonary artery adventitia of the same patient. Fibroblasts isolated from CTEPH thrombus demonstrated upregulation of genes associated with the TGF-β pathway indicating that TGF-β upregulation is associated with the intravascular remodeling process.

2020-12-31 | GSE149413 | GEO

Single cell RNA sequencing of distal thrombus tissue from CTEPH patients

Project description:Our current understanding of CTEPH pathobiology is primarily derived from cell-based studies limited by the use of specific cell markers or phenotypic modulation in cell culture. Therefore, our main objective is to identify the multiple cell types that comprise the CTEPH thrombus and to study their dysfunction. Here we used single cell RNA sequencing (scRNAseq) of tissue removed at the time of pulmonary endarterectomy (PEA) surgery from five patients to identify the multiple cell types. Our scRNAseq identify the multiple cell types including macrophages, T cells, and smooth muscle cells, that comprise CTEPH thrombus. Notably, multiple macrophage subclusters were identified but broadly split into two categories, with the larger group characterized by an upregulation of inflammatory signaling predicted to promote pulmonary vascular remodeling. Both CD4+ and CD8+ T cells were identified and likely contribute to chronic inflammation in CTEPH. Smooth muscle cells were a heterogeneous population, with a cluster of myofibroblasts that express markers of fibrosis and are predicted to arise from other smooth muscle cell clusters based on pseudotime analysis. Lastly, our analysis identified protease-activated receptor 1 (PAR1) as a potential therapeutic target that links thrombosis to chronic PE in CTEPH

2023-02-07 | GSE224143 | GEO

Gene expression profile at single cell level of pulmonary endarterectomy surgical specimens from chronic thromboembolic pulmonary hypertension (CTEPH)

Project description:Gene expression profile at single cell level of pulmonary endarterectomy surgical specimens from chronic thromboembolic pulmonary hypertension (CTEPH)

| PRJNA1131389 | ENA

Comparing CTEPH to Control and IPAH pulmonary arteries

Project description:Samples surgically extracted from CTEPH pulmonary arteries were compared to post-transplant pulmonary arteries from IPAH and failed donor pulmonary arteries from controls The goal was to determine if altered gene expression in CTEPH associated with development of chronic thrombi

2019-04-27 | GSE130391 | GEO

Expression patterns in chronic thromboembolic pulmonary hypertension

Project description:We sequenced RNA from pulmonary arteries from CTEPH, IPAH or healthy, failed donors

2019-02-18 | GSE84538 | GEO

Plasma microRNA profile in chronic thromboembolic pulmonary hypertension patients and healthy controls

Project description:We aimed to identify the ebbrantly hypothesized that circulating miRNA profile might reflect the miRNAs involved in the pathogenesis of CTEPH more comprehensively, thus could be used as candidate biomarker and shed light on the recognition of CTEPH pathogenesis.

2014-12-31 | GSE56914 | GEO

Anti-proliferative effect of selexipag active metabolite MRE-269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension

Project description:Chronic thromboembolic pulmonary hypertension (CTEPH) is a group 4 pulmonary hypertension (PH) characterized by non-resolving thromboembolism in the central pulmonary artery and vascular occlusion in the proximal and distal pulmonary artery. Medical therapy is chosen for patients who are ineligible for pulmonary endarterectomy or balloon pulmonary angioplasty or who have symptomatic residual PH after surgery or intervention. Selexipag, an oral prostacyclin receptor agonist and potent vasodilator, was approved for CTEPH in Japan in 2021. To evaluate the pharmacological effect of selexipag on vascular occlusion in CTEPH, we examined how its active metabolite MRE-269 affects platelet-derived growth factor-stimulated pulmonary arterial smooth muscle cells (PASMCs) from CTEPH patients. MRE-269 showed a more potent anti-proliferative effect on PASMCs from CTEPH patients than on those from normal subjects. DNA-binding protein inhibitor genes ID1 and ID3 were found by RNA sequencing and real-time quantitative polymerase chain reaction to be expressed at lower levels in PASMCs from CTEPH patients than in those from normal subjects and were upregulated by MRE-269 treatment. ID1 and ID3 upregulation by MRE-269 was blocked by co-incubation with a prostacyclin receptor antagonist, and ID1 knockdown by small interfering RNA transfection attenuated the anti-proliferative effect of MRE-269. ID signaling may be involved in the anti-proliferative effect of MRE-269 on PASMCs. This is the first study to demonstrate the pharmacological effects on PASMCs from CTEPH patients of a drug approved for the treatment of CTEPH. Both the vasodilatory and the anti-proliferative effect of MRE-269 may contribute to the efficacy of selexipag in CTEPH.

2022-12-27 | GSE221511 | GEO

Single cell RNA sequencing of distal thrombus tissue from CTEPH patients

Project description:Single cell RNA sequencing of distal thrombus tissue from CTEPH patients

| PRJNA929967 | ENA

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH).

Project description:This multicenter, randomized, double-blind, placebo-controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. Futility of enrollment led to early termination. Trends of improvement in favor of ambrisentan versus placebo in the primary and some secondary endpoints were observed; adverse event profiles were similar between groups.

| S-EPMC6540507 | biostudies-literature

Comparing CTEPH to Control and IPAH pulmonary arteries

Project description:Comparing CTEPH to Control and IPAH pulmonary arteries

| PRJNA539975 | ENA